Oral blockade of the platelet glycoprotein IIb/IIIa receptor: Fact or fancy?

American Heart Journal

Volumn 138, Issue 1 II, 1999, Pages

  Kereiakes, D J ^a  

^a Carl and Edyth Linder Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; ORBOFIBAN; ROXIFIBAN; SIBRAFIBAN; TICLOPIDINE; TIROFIBAN; XEMILOFIBAN;

BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; HEART INFARCTION; HUMAN; MONITORING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TRANSIENT ISCHEMIC ATTACK;

EID: 0032764887     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1053/hj.1999.v138.99080     Document Type: Conference Paper

References (25)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: I, prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
2. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-35.
3. Smith AJ, Holt RE, Fitzpatrick JB, et al. Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. Am Heart J 1996;131:434-9.
4. Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 1996;93:870-8.
5. Oldgren J, Linder R, Egberg N, et al. Variable inhibition of coagulation activity during and after heparin infusion in patients with unstable coronary artery disease [abstract]. Circulation 1996;94:I-431.
6. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
7. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
8. IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: the IMPACT-II trial. Lancet 1997;349:1422-8.
9. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
10. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
11. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
12. Simpfendorfer C, Kottke-Marchant K, Lowrie M, et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade: a randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997;96:76-81.
13. Cannon CP, McCabe CH, Borzak S, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Circulation 1998;97:340-9.
14. Kereiakes DJ, Runyon JP, Kleiman NS, et al. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab: administration for complex coronary intervention. Circulation 1996;94:906-10.
15. Kereiakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 1997;96:1117-21.
16. Kereiakes DJ, Kleiman NS, Ferguson JJ, et al. Safety and efficacy of prolonged platelet GP IIb/IIIa blockade with xemilofiban: final results of the ORBIT trial [abstract]. Circulation 1997;96:I-385.
17. Kereiakes DJ, Ferguson JJ, Masud ARZ, et al. Sustained platelet gp IIb/IIIa blockade with oral xemilofiban: final results of the ORBIT trial [abstract]. Circulation 1997;96:I-385.
18. Kereiakes DJ, Kleiman NS, Ferguson JJ, et al. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation 1998;98:1268-78.
19. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-94.
20. Searle study NG7-96-ST-045 (Xemilofiban) protocol #NG79502045; 1999. (Data on file at G.D. Searle.)
21. Oliver S, Karim A, Burns DM, Anders RJ. Effect of aspirin on orbofiban tolerability and pharmacodynamics [abstract]. XIII World Congress of Cardiology, Rio de Janeiro, Brazil, 26-30 April 1998.
22. Catella-Lawson F, Kapoor S, Skammer W, et al. Chronic inhibition of platelet glycoprotein IIb/IIIa by a new oral agent: a dose-escalation study in patients with coronary artery disease (CAD)[abstract]. 16th Congress of the international Society on Thrombosis and Haemostasis, Florence, Italy, 6-9 June 1997.
23. Coller BS. Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation 1997;96:3828-32.
24. Mascelli MA, Worley S, Veriabo NJ, et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation 1997;96:3860-6.
25. Catella-Lawson F, Kapoor S, Moretti DT, et al. Chronic oral glycoprotein IIb/ IIIa antagonism with unstable coronary artery disease [abstract]. Circulation 1998;98:I-251.